Antigen-driven T-cell activation and subsequent differentiation processes involve complex interactions among cell surface and soluble molecules, among which cytokines such as interferon-g (IFN-g), IL-2, IL-12, IL-4, granulocyte macrophage-colony-stimulating factor (GM-CSF), and IL-10 are central. [1] [2] [3] [4] [5] [6] Several types of immune cells, including dendritic cells (DCs), B cells, and NK cells, can influence the polarization of an immune response toward either a humoral or a cellular type, depending on the type of antigen, available cytokines, and the costimulatory environment. 5, [7] [8] [9] However, many of the molecules that drive a specific immune response have yet to be identified. 1, 3, 10 It is interesting that cytokines such as IL-18 can drive a type 1 helper T cell (Th1)-biased immune response in the absence of the classical cytokines. 11, 12 In contrast, the absence of certain cytokines such as GM-CSF diminishes Th1 or type 2 helper T cell (Th2) responses despite the presence of the specific driving cytokines. [13] [14] [15] [16] Thus, besides the presence of the driving cytokines, several other factors are also required for an optimal immune response. [13] [14] [15] [17] [18] [19] [20] [21] Previous studies have shown that GM-CSF, a pluripotent cytokine that acts as an immune adjuvant, can drive both humoral and cellular immune responses, apart from its several immunomodulatory functions. 13, 19, [22] [23] [24] GM-CSF has been reported to initiate activation, proliferation, and differentiation of macrophages, T cells, neutrophils, and various antigen-presenting cells (APCs). 13, 19, [22] [23] [24] This cytokine not only enhances antigen-induced immune responses but can also alter the Th1/Th2 cytokine balance. For example, mice lacking GM-CSF die rapidly from severe necrosis when exposed to an aerosol-delivered infection of Mycobacterium tuberculosis because of an inability to mount a Th1 response.
14,25 GM-CSF overexpression, however, failed to focus T cells and macrophages into sites of infection, suggesting that uncontrolled GM-CSF expression leads to dysregulation of cytokine and chemokine networks. 26 Therefore, excess GM-CSF does not induce an excessive Th1 response; very fine control of GM-CSF is needed to fight infections such as M. tuberculosis. In another study, it was shown that adenoviral-based gene transfer for the overexpression of GM-CSF promoted a transient increase in IL-4 and IL-5 and an eosinophilic inflammatory response in the lung. 27 Increased recruitment of DC, macrophages, and activated CD4 þ and CD8 þ cells was also observed, and CD69 was upregulated on neutrophils, indicative of their activation. These studies suggest that GM-CSF can promote both Th1-and Th2-type immune responses, depending on the conditions. In fact, this was demonstrated directly in a study combining GM-CSF with a herpes simplex virus (HSV) DNA vaccine, which elicited an immune response to infection with both Th1 and Th2 components. 28 Coinjection of GM-CSF with the HSV DNA induced expression of both IL-2 and IFN-g, and inhibited IL-4 production, characteristics of a Th1 response. The predominant serum IgG isotype, however, was indicative of a Th2 bias. Thus, GM-CSF favors neither a Th1 nor a Th2 response, but rather boosts both types of immune responses.
Although T cells are one of the major sources of GM-CSF, the phenotype of the GM-CSF-producing T cells has not been determined. 29, 30 It has been shown that most T cells lose the ability to synthesize GM-CSF during differentiation, 31 but the exact role of either Th1 or Th2 cytokines, such as IFN-g, IL-12, IL-4, and IL-10, in the production and regulation of GM-CSF has not been systematically investigated. Moreover, the function of GM-CSF is not well defined in activated or differentiated Th cells and its physiological relevance, especially in the Th cell response, is largely unknown. Although several Th1 and Th2 differentiation models have been proposed, the molecular mechanisms controlling the differentiation of Th1 and Th2 cells are still uncertain. [16] [17] [18] [19] [20] [22] [23] [24] [25] In addition, the exact mechanisms by which cytokines promote differentiation are still debated. Most importantly, it has been reported that Th cells can fully differentiate in the absence of the signature cytokines. Furthermore, the fact that a majority of T cells differentiated under unbiased conditions are neither of the Th1 or Th2 type has not been explained, although new Th subsets such as Th17 have recently been identified. In this study we differentiated naive CD4 þ T cells in the absence of IL-12, IFN-g, and IL-4, and thus derived a novel subset of Th cells that produce large amounts of GM-CSF. We termed these cells 'ThGM' cells. Through their abundant GM-CSF, these cells are capable of providing help to various T-cell populations to produce their own cytokines. ThGM cells are also exquisitely sensitive to activation-induced cell death (AICD). We believe that ThGM cells are important in generating an optimal immune response by their prompt and robust production of GM-CSF.
Results

Generation and characterization of ThGM cells.
Cytokines play a critical role in the differentiation of Th cells. Depletion of IL-4 and supplementation with IL-12 during differentiation in vitro leads to the preferential outgrowth of Th1 cells, whereas removal of IFN-g and IL-12 in the presence of IL-4 favors Th2 cells. 2, 32 As these cytokines are not yet expressed at the early stages of an immune response, we sought to determine the outcome of eliminating all Th1-and Th2-driving cytokines during Th cell differentiation. Accordingly, we depleted IL-12, IFN-g, and IL-4 with neutralizing antibodies during the activation of CD4 þ T cells with anti-CD3 and anti-CD28 in vitro. The Th cells thus differentiated with the inclusion of IL-2 (termed ThGM cells, as they were found to produce abundant GM-CSF; see later) were smaller in size than Th1 and Th2 cells, as indicated by reduced forward scatter on flow cytometric analysis (Figure 1a ). These cells also proliferated more slowly than Th1 and Th2 cells (Figure 1b) . When ThGM cells were analyzed for various T cell surface markers, we found a marked difference in CD45, and high levels of CD95 and CD69 (Figure 1c ) upon restimulation as compared with Th1 and Th2 cells. Therefore, ThGM cells are phenotypically distinct from Th1 and Th2 cells.
ThGM cells promote cytokine production by other T cells. To test the ability of ThGM cells to influence other types of T cells, we co-cultured differentiated ThGM cells with CD4 þ T cells, CD8 þ T cells, type 1 cytotoxic T cells (Tc1), type 2 cytotoxic T cells (Tc2), Th1 cells, or Th2 cells. We found that each of these cell types produce significantly higher levels of activation-induced cytokines in the presence of ThGM cells (Figures 2a and b) . ThGM cells also promoted anti-CD3 activation-induced cytokine production by undifferentiated CD4 þ T cells and CD8 þ T cells (Figure 2a) . We noticed that ThGM-promoted IFN-g production was more effective in CD4 þ cells than in CD8 þ cells, whereas the increase in IL-4 and IL-5 was greater in CD8 þ cells (Figure 2a ). In addition, Tc1 cells produced more tumor necrosis factor-a (TNF-a) whereas Tc2 cells produced more IL-4 and IL-5 in the presence of ThGM (Figure 2a) . To examine the potency of ThGM cells, their density in culture was varied. We found that even when added at o25% of the total cells in co-culture, ThGM cells were still able to boost cytokine production by other cell types (Figure 2b ), suggesting a very potent capacity to enhance cytokine production in other T-cell populations. To verify our immunoassay, we also tested cytokine expression by intracellular staining and flow cytometry. The results showed that ThGM cells boosted production of type 1 cytokines in Th1 and Tc1 cells (Figure 2c ), or production of type 2 cytokines in Th2 (Figure 2c ), whereas ThGM cells (the cells were separated by CSFE staining) themselves produced very little of these cytokines (Figures 2a and b) .
ThGM cells produce large amounts of GM-CSF. To further characterize ThGM cells, total RNA from restimulated and control ThGM cells was analyzed for the expression of 50 000 genes by microarray. The 65 most increased genes and 50 most decreased genes are listed in Supplementary Tables S1 and S2. One significant finding was the robust expression of GM-CSF in restimulated ThGM cells at a level greater than any other cytokine. Therefore, we next examined GM-CSF protein levels in the supernatants of cultures of activated ThGM, Th1, and Th2 cells, using the Luminex multiplex microbead-based cytokine assay by simultaneous assay of 18 different cytokines (IL-2, IL-3, IL-4, IL-5, IL-6, IL-12(p40), IL-12(p70), GM-CSF, IFN-g, TNF-a, and so on). We found that activated ThGM cells produced insignificant amounts of IFN-g or IL-4 as compared with Th1 or Th2 cells (Figure 3a) . ThGM cells did, however, produce strikingly large amounts of GM-CSF at levels several times higher than did Th1 or Th2 cells (Figure 3a) . Although GM-CSF is well known as a pluripotent cytokine and has been used in various approaches to boost immune responses, its major source is still unknown. 33 To verify that ThGM cells produce high levels of GM-CSF, we did flow cytometric analysis of intracellular GM-CSF staining in ThGM and found significantly greater intensity of GM-CSF staining in ThGM cells than in Th1 or Th2 cells at 6 h after restimulation (Figure 3b ). To further confirm GM-CSF expression in ThGM cells, we performed real-time RT-PCR at 6 h after restimulation. ThGM cells were found to express much higher levels of GM-CSF mRNA as compared with Th1 or Th2 cells (Figure 3c ). Hence, ThGM cells, differentiated in the complete absence of all driving cytokines, uniquely produce large amounts of GM-CSF. Interestingly, we also found that addition of any one of the Th1 or Th2 signature cytokines at 2 days after differentiation under cytokine-deprived condition of CD4 þ T cells resulted in cells that expressed much less GM-CSF (Figure 3d ), indicating that ThGM cells develop only in the absence of Th1-and Th2-driving cytokines.
We further examined the expression of T-bet and GATA-3 in ThGM cells. Interestingly, unlike Th1 cells, ThGM cells did not express T-bet (Supplementary Figure S1) . Unlike Th2 cells, ThGM cells did not express GATA-3 (Supplementary Figure S2) . Because IFN-g or IL-4 impairs the development of Th17 cells and Treg cells, [34] [35] [36] it is possible that blocking both cytokines would result in the generation of these two T-cell subtypes. Therefore, we also examined the expression of RORgt and FoxP3. We found that neither was detected in ThGM cells (Supplementary Figures S3 and S4 ). In addition, unlike Th17 cells, IL-17 cytokine level in ThGM cells was very low, comparable to Th1 cells (Supplementary Figure S5) . Taking together, our data strongly suggest that ThGM cells are distinct from the known phenotypes of Th1, Th2, Th17, or Treg cells. As the transcription factors NFATc1, AP-1 and RUNX-1 were reported to bind to the promoter of GM-CSF and regulate its production, 37, 38 we examined these genes and found that NFATc1, AP-1, and RUNX-1 were expressed in ThGM cells, although at different levels (Supplementary Figure S6) . This result indicates that these genes may be involved in ThGM differentiation, although further investigation on the molecular level is still required to clarify the mechanism of the transcription factor. To determine when in their differentiation ThGM cells acquire their helper ability, we performed kinetic and functional analyses. First, ThGM cells at various stages of differentiation (days 2, 4, and 6) were co-cultured with unbiased CD8 þ cells, and the effect of ThGM cells on the ability of the latter cells to produce TNF-a was tested. We found that TNF-a production reached a maximum on day 6, indicating that ThGM cells require 6 days for full functionality (Figure 4c ). Therefore, ThGM cells require 6 days for complete differentiation into GM-CSF-secreting ThGM cells (Figure 4c ).
GM-CSF mediates T-cell help by
To further investigate the role of ThGM-secreted GM-CSF in promoting the function of other Th cells, we examined the effect of recombinant GM-CSF added to differentiated Th cell subsets. When Th cells were preincubated with GM-CSF (10 ng/ml) for just 15 min before restimulation with anti-CD3 in the presence of GM-CSF, the production of IFN-g and IL-4 by Th1 and Th2 cells, respectively, was nearly doubled under this condition, they also produced IFN-g in the presence of high-amount GM-CSF (Figure 4d ).
ThGM cells are highly susceptible to AICD. ThGM cells provide help to multiple T-cell populations through their secretion of GM-CSF, a function they acquire after B6 days of activation. Inevitably, the continued presence or persistence of this type of Th cells would be expected to result in a highly active immune response, and an effective control mechanism should exist. Thus, we asked whether ThGM cells are susceptible to deletion by AICD. We recently studied AICD in Th1 and Th2 cells and found that a proportion of both cell types undergo AICD, B60% in Th1 and 40% in Th2 cells after 12 h. 39 When tested for AICD in response to restimulation with anti-CD3, ThGM cells were found to be exquisitely sensitive to apoptosis induction. More than 80% of ThGM cells underwent AICD within 18 h of activation, as compared with only 57% of Th1 cells and 42% of Th2 cells (Figure 5a ) suggesting that ThGM cells are exquisitely sensitive to AICD. We further checked the dose response of stimulus strength in ThGM AICD and found that ThGM cells reached maximum apoptosis at 1 mg/ml concentration of anti-CD3 (Supplementary Figure S7) . Notably, AICD in ThGM cells decreased at 5 mg/ml anti-CD3 as compared with the 1 mg/ml group. This is understandable that stimulus overstrength inhibits ACID.
Interestingly, although AICD could be blocked in Th1 cells by anti-FasL and zVAD, a pan-caspase inhibitor, 39 these reagents could only partially rescue ThGM cells from AICD. Inhibition of TRAIL and granzyme B that are known to affect apoptosis had no effect on AICD in ThGM cells (Figure 5b ). Our microarray data showed that many proapoptotic genes including some members of the Bcl-2 BH3-only domain family of proteins were upregulated in restimulated ThGM cells (Supplementary Table S1 ). Real-time Q-PCR and western blotting analysis for these proapoptotic genes confirmed that Bim and Bid are indeed upregulated, whereas Bik is not (Figure 5c ). Moreover, we also found that all the classical apoptosis markers, namely, annexin-V binding (Figure 5d ), DNA fragmentation, and viability (Figure 5e restimulated ThGM. When co-cultured with Th2 cells, we found that more ThGM cells became PI þ upon restimulation than Th2 cells (Figure 5f ). We also found that ThGM cells are sensitive to dexamethasone-induced cell death (Supplementary Figure S8) . Interestingly, the combination of dexamethasone (at the lower concentration with less toxicity) and anti-CD3 only partially reduced AICD in ThGM cells (Supplementary Figure S9) , compared with the group restimulated with anti-CD3 alone. However, when ant-CD3 and dexamethasone were used together in A1.1 T-cell hybridoma, which solely undergo FasL-mediated apoptosis, 40 AICD was completely blocked (Supplementary Figure S9) . As dexamethasone was reported to inhibit FasL expression, 41 these results may indicate that unlike in A1.1 T cells, AICD in ThGM cells is not solely dependent on Fas/FasL interaction. Thus, our data suggests that AICD in ThGM cells is through a distinct mechanism that does not involve TRAIL or granzyme B, but does act through caspases and partially through FasL/Fas.
GM-CSF promotes the differentiation of ThGM cells.
GM-CSF is well known to promote the differentiation and function of DCs. 42 Although it is suspected to be important in T-cell functions, [43] [44] [45] the effects of GM-CSF on T cells is not well understood. Therefore, we examined the effect of GM-CSF on the differentiation of CD4 þ T cells. CD4 þ T cells differentiated in the presence of GM-CSF, without Th1-or Th2-biasing conditions, exhibited similar properties as ThGM cells, which are differentiated with antibody neutralization of IL-4, IL12, and IFNg, as evidenced by their rapid apoptosis and cytokine production profiles, especially high production of GM-CSF upon restimulation (Figures 6a  and b) . Therefore, GM-CSF sensitizes differentiating CD4 þ T cells to AICD. This novel property of GM-CSF seems somewhat incompatible with its known ability to promote T-cell survival following irradiation. From our results, we infer that the continued presence of IL-2 in the GM-CSFdifferentiated cells did not contribute to the high sensitivity of these cells to AICD (Figure 6a ). Moreover, we found that spontaneous death in these cells was significantly higher by day 6, rendering them unusable for co-culture studies. 
Pluripotent effect of GM-CSF in T cells. We have shown that ThGM cells help boost cytokine production by many different T-cell subpopulations and that this function is
Discussion
The development of an immune response involves the concerted action of several different cell types.
1,2 Typically, exogenous antigens are presented to T cells by APCs and DCs. TCR binding of the MHC class II peptide complex along with the interaction of appropriate costimulatory molecules activates naive T cells, which then differentiate into Th1-or Th2-type cells, depending on the cytokine environment. 1, 5, 18, 46 After antigen exposure, the early activation process is not equivalent for every T cell, as the cells are influenced by a variety of factors that further influence their response. [1] [2] [3] [4] [5] [6] [7] These factors include the types and doses of antigen, duration and site of exposure, cell type responsible for presentation, genetic factors, and the cytokine environment. As several of these factors come into play during an immune response, it is very unlikely that every T cell could experience the same schooling to create a perfectly coordinated response. Rather, each cell is probably exposed to a somewhat unique combination of factors. Hence, an optimal immune response is likely a stochastic event that is influenced by multiple factors, including the presence of DCs and differentiating cytokines. [9] [10] [11] To examine the fate of Th cells exposed to a nonbiased cytokine environment, as might occur at the initiation of an immune response before Th cells have had a chance to differentiate and produce their signature cytokines, we differentiated CD4 þ T cells in vitro in the absence of Th1/ Th2-biasing cytokines by adding antibodies to neutralize IL-12, IL-4, and IFN-g. This resulted in a distinct type of Th cells that we termed ThGM cells, as they produced large amounts of GM-CSF. These cells have a unique cytokine production profile and are exquisitely susceptible to apoptosis. Not surprisingly, we found that the presence of IL-2 was mandatory for growth during the differentiation of ThGM cells, and mere ligation of the TCR and costimulation through CD28 was not sufficient to support cell viability and activation. 12 In contrast, addition of GM-CSF allowed better survival of CD4 þ T cells during activation, and also resulted in these cells ultimately being highly susceptible to AICD. Interestingly, addition of IL-2 along with GM-CSF resulted in highly potent cytokine secretors on restimulation. ThGM cells were capable of boosting the production of cytokines by various types of T cells. We found that the abundant production of GM-CSF by these cells was responsible for their helper function.
GM-CSF and IL-3 are two cytokines produced by activated T cells that are potent growth factors for multipotent hematopoietic progenitors. Upon binding to their receptors (composed of a cytokine-specific a-subunit and a common b-subunit shared among the IL-5 receptor and IL-3 receptor), these cytokines generate both mitogenic and antiapoptotic signals. Interestingly, cytokine-specific receptors for GM-CSF have not been shown on T cells. Yet, the diminished production of IFN-g by CD8 þ T cells from GM-CSF À / À mice in response to LPS can be restored by GM-CSF injection. This provides direct evidence that the deficiency is actually in the T-cell component and that the biological effect on T cells is indirect. The lack of expression of the a-chain for the GM-CSF receptor in T cells desensitizes them to low levels of GM-CSF, notwithstanding the presence of the b-chain. Still, the high levels of GM-CSF produced by ThGM cells (20-30 ng/ml) and the proximity of T cells in co-culture allows the T cells to respond to ThGM cells, as we have demonstrated here.
We have found that CD4 þ or CD8 þ cells, or Tc1 or Tc2 cells, co-cultured with ThGM cells boosts their production of both type 1 and type 2 cytokines via the action of GM-CSF secreted by the ThGM cells. Maximal GM-CSF production was seen from ThGM cells that underwent 3 days of activation followed by 2 days of resting, and then restimulation. These cells showed similar sensitivity to apoptosis as CD4 þ T cells grown with GM-CSF alone. Thus, ThGM cells are highly sensitive to AICD, and this might be attributable to exposure to autocrined GM-CSF.
As ThGM cells seem to provide help to all T-cell subsets that we have investigated, we tested whether ThGM cells themselves are capable of producing the cytokines induced in other cell types. Analysis of a total of 18 cytokines showed that TCR-restimulated ThGM cells produced low or undetectable levels of a majority of these cytokines. In contrast, GM-CSF was abundantly produced, at levels at least 5-to 10-fold higher than that from Th1 or Th2 cells. Moreover, even small amounts of GM-CSF, be it from ThGM cell supernatant or recombinant cytokine, elicited a significant response in Th1 and Th2 cells, as evidenced by increased production of IL-4 and IFN-g by both cell types. Like ThGM cells, CD4
þ cells that were differentiated in the presence of exogenous GM-CSF, regardless of any other cytokines, were highly prone to AICD (Figure 6a) . Thus, the presence of GM-CSF during CD4 þ T-cell differentiation renders them susceptible to AICD.
The adoptive transfer of ThGM cells into OVA-immunized mice showed that these cells were able to enhance cytokine production by splenocytes freshly isolated from these mice after challenge with OVA. Our data suggest that GM-CSF-secreting ThGM cells could be utilized as an effective modulator of the immune response. It has been reported that GM-CSF primes and activates basophils and neutrophils, 47 which may shed some light on further exploration of ThGM promoting T-cell response. Further elucidation of the mechanism of ThGM-mediated effects on other Th cell types may lead to the possible use of ThGM cells for pathogen-specific treatment of immunocompromised patients by ex vivo expansion and adoptive transfer of these cells.
Materials and Methods
Reagents and mice. Biotin-labeled antibodies against IFN-g, IL-4, and TNF-a, and phycoerythrin (PE)-labeled antibodies against IL-5 and IL-10 were purchased from eBiosciences (La Jolla, CA, USA). Neutralizing antibodies against IFN-g and IL-4 were produced by Harlan Bioproducts for Science (Indianapolis, IN, USA) and anti-IL-12 was from eBiosciences. Chemiluminescence was from Amersham Biosciences (Piscataway, NJ, USA). Brefeldin A and CFSE were from Sigma-Aldrich Corporation (St. Louis, MO, USA). Cytofix and cytoperm were from BD Biosciences (San Jose, CA, USA).
Anti-murine FasL (MFL3), and FITC-or PE-conjugated Annexin-V were purchased from BD Biosciences/Pharmingen (La Jolla, CA, USA). DR5 was a kind gift of Dr. Youhai Chen, University of Pennsylvania (Philadelphia, PA, USA). The GrB inhibitor Z-AAD-CMK was from Calbiochem (San Diego, CA, USA). Pan-caspase inhibitor z-VAD was from Enzyme Systems (Livermore, CA, USA). TR6 recombinant protein was from Dr. Paul Moore, Human Genome Sciences (Rockville, MD, USA). The DPP-I inhibitor Gly-Phe-CHN2 (MP Biochemicals, Aurora, OH, USA) was used to inhibit cathepsin C activity. Antibody against Bim, Bid, and Bik was from eBiosciences.
BALB/c mice at 6 weeks of age were obtained from the National Cancer Institute (Frederick, MD, USA) and maintained in a pathogen-free facility at the Robert Wood Johnson Medical School Vivarium, with food and water provided ad libitum. Animals were used 1 week after shipping and were matched for gender and age in each experiment. All animal experiments were carried out under protocols approved by the IACUC at Robert Wood Johnson Medical School.
Differentiation of Th and cytotoxic subsets. Naive CD4 þ or CD8 þ T cells were purified from splenocytes of BALB/c mice by negative selection using immunoaffinity columns (mouse T-cell CD4 þ or CD8 þ subset isolation kit, R&D Systems, Minneapolis, MN, USA) and differentiated into Th subsets. Briefly, CD4 þ lymphocytes (1 Â 10 6 /ml) were activated with plastic-bound anti-CD3 (coated at 1 mg/ml) and anti-CD28 (soluble, 2 mg/ml). In addition, anti-IL-4 (10 mg/ml) was included for Th1 cells, whereas anti-IL-12 and anti-IFN-g (10 mg/ml each) were supplied for Th2 cells, as performed previously 1, 3, 10 ). Th0 cells were cells derived from naive T cells and differentiated without cytokine skewing. For differentiation of ThGM cells, anti-IL-4, anti-IL-12, and anti-IFN-g (10 mg/ml each) were included in the culture. After 24 h, IL-2 (100 U/ml) was added to all cultures, and IL-12 (10 ng/ml) and IL-4 (5 ng/ml) were added to Th1 and Th2 cultures, respectively. Tc1 and Tc2 subsets were differentiated from CD8 þ lymphocytes in the similar protocol to Th1 and Th2 differentiation. All T-cell cultures were maintained in RPMI-1640 medium supplemented with 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 10% heat-inactivated FBS, and 10 mM Gentamycin. Cells were subdivided in a 1 : 4 ratio 3 days later and maintained under the above cytokine or antibody conditions in the absence of anti-CD3 and anti-CD28 for another 3 days. Unbiased activation of CD4 þ and CD8 þ cells was carried out in a similar fashion, except that no cytokine neutralization antibodies were used.
Detection of cell surface and intracellular proteins. ThGM cells were analyzed by flow cytometry for gross morphology by forward scatter (FSC) and side scatter (SSC). The Th cell subsets were restimulated with anti-CD3 and tested for proliferation by standard 3 H-thymidine incorporation. Surface marker expression was detected by direct immunofluorescence after blocking Fc-g receptors with unlabeled anti-CD16/32 (BD Biosciences), and visualized by flow cytometry using a FACScan (BD Immunocytometry Systems, San Jose, CA, USA). Intracellular cytokine expression was detected by staining as described previously. 46 Briefly, cells were treated with brefeldin A (10 mg/ml) during the last
Helper T cells produce GM-CSF J Zhang et al 4-6 h of their restimulation with anti-CD3, fixed with 1% paraformaldehyde for 15 min., washed, and resuspended in 50 ml of permeabilization buffer (0.5% saponin in PBS, with 2% FCS, and 0.1% sodium azide). After incubating with biotin-labeled rat anti-murine IFN-g or anti-GM-CSF followed by PE-conjugated streptavidin, staining was quantitated by flow cytometry. IL-10, IL-5, and TNF-g were detected using directly fluorochrome-conjugated antibodies. Nonspecific binding was determined using isotype-matched nonspecific control antibodies.
Blocking and analysis of apoptosis. Differentiated T cells (10 6 cells/ml) were analyzed for apoptosis after activation in the presence or absence of the following reagents: z-VAD (5-250 mM), anti-FasL antibody (MFL3, 50-5000 ng/ml), FasL-blocking TR6 recombinant protein (50-5000 ng/ml), TRAIL-binding Osteoprotegerin (OPG, 50-1000 ng/ml, R&D Systems), TRAIL-blocking DR5 fusion protein (5-20 mg /ml), DMSO (0.1-5%), or the DPP-I inhibitor Gly-Phe-CHN2 (5-250 mM). Each reagent was added 15-20 min before restimulation. Apoptosis was analyzed by PI staining for hypodiploid DNA content. 48 Briefly, cells were washed with cold PBS, and then resuspended and diluted to 250 ml in DNA staining buffer consisting of 0.5% saponin, 50 mg/ml propidium iodide, and 0.1 mg/ml RNase A before analysis by flow cytometry for the percentage of cells in the hypodiploid region on histogram.
RNA extraction and real-time PCR. Total RNA from was isolated from cell pellets using an RNeasy Mini Kit (QIAGEN, Valencia, CA, USA). Genomic DNA was then removed from total RNA before cDNA synthesis using the RNaseFree DNase during RNA purification. First-strand cDNA synthesis was performed for each RNA sample using Sensiscript RT Kit (QIAGEN). Random hexamers were then used to prime cDNA synthesis. Messenger RNA expression of the genes of interest was determined by real-time PCR (Mx4000, Stratagene, La Jolla, CA, USA) using SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA). Thermocycler conditions included an initial hold at 50 1C for 2 min, then 95 1C for 10 min, followed by a 2-step PCR program of 95 1C for 15 s and 60 1C for 60 s repeated for 40 cycles. Levels of b-actin were used as endogenous controls to normalize the total amount of RNA in each sample; all values are expressed as fold-increase relative to b-actin RNA.
Western blotting analysis. To analyze protein expression, cells were washed 3 times with PBS and the pellet resuspended in 100 ml lysis buffer. Whole cell protein was extracted and immunoblotting was conducted according to the manufacturer's protocol (Cell Signaling Technology, Danvers, MA, USA). Briefly, 30 mg of protein extract was added to 3 Â sample buffer (125 mM Tris-HCl, pH 6.8, 1% SDS, 2% 2-ME, and 0.01% bromophenol blue), boiled for 5 min, and loaded onto a 10% SDS-polyacrylamide gel. After separation, proteins were transferred onto a nitrocellose membrane by electroblotting (Bio-Rad, Hercules, CA, USA). The membrane was blocked with 5% nonfat milk in TBS with 0.1% (w/v) Tween-20 for 1 h at room temperature, probed for 2 h with the specified primary Abs against corresponding proteins, and incubated with a HRP-linked secondary Ab for 1 h before the membrane was washed with 1 Â TBS with Tween-20 for 1 h. Protein bands were visualized by chemiluminescence (Amersham Biosciences). The membrane was then stripped according to the manufacturer's protocol (Amersham Biosciences) and reprobed with Ab for a control protein, usually b-actin (Sigma-Aldrich).
Detection of cytokines. Cytokine levels in culture supernatants were determined by multiplexed bead array immunoassay using Luminex technology (Bio-Plex; Bio-Rad Laboratories).
T-cell co-cultures. CD4
þ , CD8 þ , Th1, Th2, Tc1 or Tc2 cells were incubated at graded ratios with ThGM cells on anti-CD3-coated or control plates (final density of 1 Â 10 6 cells/ml). To distinguish cell types in the co-cultures, one cell type was labeled with CFSE (1 mM for 10 min, then washed thrice with ice-cold medium). Alternatively, one cell type was separated from the other in the coculture by a semipermeable membrane using Transwell inserts.
Immunization and adoptive transfer of Th cells. BALB/c mice were immunized by tail base injection of 50 l of OVA (10 g in 50 l saline) emulsified in incomplete Freund's adjuvant. Four groups (Th1, Th2, ThGM, or Th0 cells) of T effector cells, derived from syngeneic BALB/c donor mice, were differentiated from initial 2.5 Â 10 6 T cells and prestained with CFSE and injected i.v. into the immunized BALB/c mice, with the fifth group of no T-cell injection as a control.
Subsequently, T lymphocytes were harvested on day 7, and CD4 þ T cells were purified. Then, non-CFSE-stained recipient CD4 þ T cells were sorted out and stimulated (7.5 Â 10 6 cells/ml) with OVA (10 mg/ml)-pulsed APCs from syngeneic BALB/c mice. Supernatant medium was collected after 48 h and assayed for various cytokines.
Statistical analysis. Statistical significance was assessed by two-tailed Student's t-test or analysis of variance (ANOVA) for repeated measures.
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